Phase II Study Of Neoadjuvant Pegylated Liposomal Doxorubicin And Cyclophosphamide ± Trastuzumab Followed By Docetaxel In Locally Advanced Breast Cancer

Wick W , Puduvalli VK , Chamberlain MC , van den Bent MJ , [14] Carpentier AF , Cher LM , et al . Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma . Expert Rev Anticancer Ther 2010 ; 28 : 1168 – 74 . Batchelor TT , Mulholland P , Neyns B , Nabors LB , [15] Campone M , Wick A , et al . Phase III randomized trial comparing the effi cacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma . J Clin Oncol 2013 ; 31 : 3212 – 8 . Thompson EM , Frenkel EP , Neuwelt EA . The paradoxical [16] effect of bevacizumab in the therapy of malignant gliomas . Neurology 2011 ; 76 : 87 – 93 . Verhoeff JJ , van Tellingen O , Claes A , Stalpers LJ , [17] van Linde ME , Richel DJ , et al . Concerns about antiangiogenic treatment in patients with glioblastoma multiforme . BMC Cancer 2009 ; 9 : 444 . Claes A , Wesseling P , Jeuken J , Maass C , Heerschap A , [18] Leenders WP . Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization . Mol Cancer Therapeut 2008 ; 7 : 71 – 8 . Van der Veldt AA , Lubberink M , Bahce I , Walraven M , de [19] Boer MP , Greuter HN , et al . Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs . Cancer Cell 2012 ; 21 : 82 – 91 . Reardon DA , Herndon JE , 2nd , Peters KB , Desjardins A , [20] Coan A , Lou E , et al . Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients . Br J Cancer 2012 ; 107 : 1481 – 7 . Reardon DA , Herndon JE , 2nd , Peters K , Desjardins A , [21] Coan A , Lou E , et al . Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients . J Neurooncol 2012 ; 107 : 213 – 21 . Wiestler B , Radbruch A , Osswald M , Combs SE , Jungk C , [22] Winkler F , et al . Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma . J Neurooncol 2014 ; 117 : 85 – 92 .